(CYTR) to Present at the Sixth Annual LD MICRO “Main Event” Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A. Kriegsman and Vice President of Business Development David J. Haen will present at the 6^th Annual LD MICRO “Main Event” Conference on Tuesday, December 3^rd, 2013 at 4:00 p.m. Pacific time. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles.

Mr. Kriegsman and Mr. Haen will be available for one-on-one meetings with the investment community on Tuesday, December 3^rd. Please contact LD Micro organizers if you would like to arrange a meeting.

Interested parties can access the audio webcast with slide presentation at http://www.cytrx.com/investors/presentations. An archived presentation will be available for 90 days.

About LD MICRO

LD MICRO is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks, as well as comprehensive reports on select companies throughout the year. The firm also hosts the LD MICRO Micro-Cap Growth Conference for investors in December of each year. This year’s conference will feature presentations by over 225 publicly-traded companies and is expected to attract more than 1,000 attendees.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is conducting a global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and has completed a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx plans to initiate under a special protocol assessment a potential pivotal Phase 3 global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx also has initiated a Phase 2 clinical trial with aldoxorubicin in patients with late-stage glioblastoma (brain cancer) and is initiating a Phase 2 clinical trial for AIDS-related Kaposi’s sarcoma. CytRx plans to expand its pipeline of oncology candidates based on a linker platform technology that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites. CytRx also has rights to two additional drug candidates, tamibarotene and bafetinib. CytRx completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about CytRx Corporation, visit www.cytrx.com.